INTRODUCTION
Bone sarcomas are rare primary bone malignancies, accounting for less than 0.2% of malignant tumours. Osteosarcoma and Ewing sarcoma have a peak incidence in adolescence, with a second peak in osteosarcoma over 60 years osteosarcoma [1] [2] [3] . Chondrosarcoma is the most frequently occurring bone sarcoma of adulthood [1] . In adolescents, osteosarcoma develops most commonly in lower extremity long bones; in older patients, there is an increased incidence of craniofacial and axial tumours [1] . Ewing sarcoma may involve any bone and also arise less commonly in soft tissues with about 50% of patients developing extremity tumours, and 25% of pelvic primary tumours. Pain is the most common presenting symptom for patients with bone tumours, but delays in diagnosis are common and patients must be referred to specialist centres for diagnosis and management.
OSTEOSARCOMA
Conventional high-grade osteosarcoma is the most common histologic type, accounting for approximately 75% of all cases, with subtypes classified according to the dominant matrix-producing cells (Table 1) [4, 5] . Other rarer subtypes of highgrade central osteosarcomas include telangiectatic and small cell variants. Intermediate and low-grade subtypes also exist that have a much lower rate of metastasis and greater overall survival (OS, Table 1 ). All patients should be staged for bone and lung metastases.
61% with multiagent therapy [6] . Subsequently, a multitude of clinical trials have augmented therapy via dose intensification and addition of chemotherapeutic agents. However, survival rates have largely plateaued. Five-year survival of patients with resectable disease is approximately 70% with a combination of methotrexate, adriamycin and cisplatin (MAP) considered to be the standard of care both in USA and Europe [7,8 && ]. Complete surgical resection of the primary site and metastatic disease remains essential for cure. Primary tumour resection should be carried out by experts in surgical reconstruction to preserve function, but the priority is to achieve adequate surgical margins as intralesional or marginal margins increase local recurrence rate, which is then associated with reduced OS [9] . Limb salvage is feasible in most patients with extremity tumours, more challenging are those with pelvic and spinal tumours wherein complete resection may be highly morbid or not possible [10] .
What is the influence of histological response to chemotherapy on management of osteosarcoma?
Pathological response to neoadjuvant chemotherapy is an important prognostic factor in osteosarcoma and formed the basis for the global EURAMOS-1 study [9] . Patients with a good response (>90% necrosis) were randomized to the addition of pegylated interferon to MAP chemotherapy and those with a poor response a more intensive regimen incorporating ifosfamide and etoposide (MAPIE). Neither treatment improved survival, with MAPIE increasing toxicity and incidence of second malignancies [8 && ,11 && ]. There is therefore no evidence that chemotherapy should be changed on the basis of histological response in resectable osteosarcoma treated with MAP. For patients with rarer subtypes of osteosarcoma, including craniofacial tumours, the significance of pathological response to chemotherapy is unknown.
What is the role of mifamurtide in osteosarcoma?
Mifamurtide is an immune-stimulating agent that may reduce incidence of lung metastases in osteosarcoma via activation of macrophages. A large randomized study investigating the addition of ifosfamide as well as mifamurtide to MAP showed no benefit for addition of ifosfamide but an increase in OS for patients treated with mifamurtide [12, 13] . However, a consensus on interpretation of the data from this study has not been reached, leading to absence of regulatory approval in the USA and variable use across Europe. In the metastatic setting, a limited study failed to demonstrate a significant improvement in outcome [14] . The French sarcoma group is currently investigating its role in patients with high-risk osteosarcoma (metastatic or localized disease with poor histologic response to neoadjuvant chemotherapy) French Sarcome13/0S2016. This randomized trial may provide further data on the benefit of mifamurtide, at least in this patient subset.
What is the role of radiotherapy in osteosarcoma?
Although osteosarcoma is regarded as a radioresistant disease, it can be beneficial for symptom control in the palliative setting and considered when a primary tumour is unresectable, and when it should be considered in combination with chemotherapy [15] . Experience of proton beam therapy (PBT) and carbon ion radiotherapy (CIRT) is increasing for those with inoperable or challenging primary sites
KEY POINTS
Primary bone sarcomas require complex management that should be undertaken in specialist centres only.
There is no evidence that altering chemotherapy on the basis of pathological response to chemotherapy improves outcome in patients with resectable osteosarcoma.
High-dose chemotherapy with stem cell support improves outcome in selected Ewing sarcoma patients with high-risk localized disease.
Collaborative studies and randomized trials are required to validate novel therapies and radiotherapy techniques. How should less common subtypes of osteosarcoma be treated?
Craniofacial osteosarcoma accounts for approximately 10% of osteosarcoma, becoming more frequent in older patients. Complete resection significantly improves local control and outcome [20, 21] . The role of chemotherapy is less clear; however, favourable outcomes have been demonstrated with the use of standard regimens and should be considered [20, 22] . Due to the morbidity of surgery, delivery of all chemotherapy prior to surgery may be valuable with PET imaging reported to aid monitoring to ensure ongoing benefit and plan timing of surgery [23] . For patients with suspected low-grade osteosarcoma, upfront wide resection is recommended for confirmation of biopsy results, and as there is no demonstrated value for chemotherapy, patients should undergo surveillance. There is little evidence to support the use of chemotherapy in patients with periosteal osteosarcoma if no highgrade component is demonstrated [24] .
What is the optimal management for patients with metastatic and recurrent osteosarcoma?
Approximately 20% of patients have metastatic disease at diagnosis [9] . For those with only lung metastases, cure is achievable if disease is resectable [25] . Patients who develop lung metastases after completion of first-line therapy, particularly if there is small volume disease and a longer disease-free internal, should be considered for resection as 5 years survival can be 40% in those who achieve a second surgical remission [26] . Focal ablation techniques have been demonstrated to achieve local control of small peripheral lung metastases; however, randomized studies are required to define their role in the curative management of patients [27, 28] . Patients with bone metastases have a much poorer outlook and consideration should be given to maintenance of quality of life. Chemotherapy, usually including ifosfamide, is commonly used for patients with recurrent disease with symptomatic benefit observed in many patients and median OS times of approximately 1 year but at the cost of significant toxicity [29, 30] . Gemcitabine alone or in combination docetaxel also has activity in osteosarcoma [31, 32] . Phase II studies investigating novel agents in patients with relapsed osteosarcoma have rarely reported positive results. A pooled analysis of seven phase II trials conducted by Children's Oncology Group (COG) and its collaborative groups that included strata for recurrent/refractory osteosarcoma with measurable disease demonstrated a 4-month EFS of 12%, with radiographic responses observed in only three of the trials [33 & ].
What are the emerging targets for osteosarcoma?
Several groups have undertaken genomic sequence analysis of osteosarcoma samples to further understand biology and identify molecular targets for therapy. These investigations have revealed significant genomic complexity and profound heterogeneity that makes identification of specific targets challenging. Nearly all osteosarcoma have alterations of TP53 or associated pathway genes, and mutations in RB1 and deletions of CDKN2A/B are common [34, 35] . Alterations of members of the PI3K/mTOR pathways were also identified in 24% of samples in one cohort [35] . The largest sequencing study of osteosarcoma to date identified mutations in insulin-like growth factor (IGF) signalling genes in 7% of cases and IGF1 receptor (IGF1R) amplification in 14% of tumours [36 && ]. Previous studies involving IFGR inhibitors in osteosarcoma did not report significant activity but, if these findings are validated, the presence of a potential biomarker makes reconsideration a possibility. FGFR amplification is observed in 8% of OS patients, associated with a poor histological response to treatment, also providing a potential target for investigation. An exome sequencing study revealed a potential role for Poly (ADP-ribose) polymerase (PARP) inhibition in osteosarcoma, with a 'BRCAness phenotype' demonstrated in a cohort of patients and preclinical evidence of PARP inhibitor activity [37] [38] [39] . These findings require independent validation but give promise for future clinical trials.
Despite a mutation rate higher than other paediatric cancers, responses to checkpoint inhibitors have been disappointing. Approximately 25% of osteosarcoma express PDL1 with expression correlating with metastasis and worse outcome [40] . However, only one of 22 patients had a response to pembroluzimab with a progression-free survival (PFS) rate of 24% at 8 weeks [41 && ]. Combination checkpoint studies are ongoing and may reveal benefit in selected patients.
Several clinical trials have investigated oral tyrosine kinase inhibitors, particularly those that inhibit vascular endothelial growth factor (VEGF), plateletderived growth factor (PDGR) and mTOR/PI3K. A phase II study of sorafenib demonstrated a 45% 6-month PFS in patients with recurrent, metastatic osteosarcoma as did a combination of sorafenib with everolimus, whilst a recent study of gemcitabine and sirolimus demonstrated a PFS of 44% at 4 months [42,43,44 & ]. Correlative biomarker studies suggest that the treatment may be worth further study in selected patients. Other studies evaluating regorafenib and lenvatinib are ongoing. Denosumab, a human mAb that targets the RANKL, is currently under evaluation for patients with recurrent osteosarcoma as is a study of an antibody to the disialogangliosid, GD2, based on evidence that osteosarcoma has high GD2 expression [45, 46] .
EWING SARCOMA
Ewing sarcoma is a small round cell sarcoma, the main driver being the reciprocal translocation between the EWSR1 and FLI1 genes (EWSR1-FLI1). However, in approximately 10% of patients, EWSR1 is fused with other ETS transcription factors, including ERG, ETV1, ETV4 or FEV [47] . All patients require staging that includes imaging of lungs, bone and bone marrow with 20% patients having metastases.
CURRENT MANAGEMENT
The incorporation of multiagent chemotherapy with an induction regimen, local therapy (surgery, radiation therapy or both) and consolidation therapy is based on results from clinical trials conducted by collaborative groups over several decades. OS for patients with localized disease now approaches 65-75%; however, acute and long-term toxicities of therapy remain substantial. Outcome for patients with metastatic disease, particularly those with extrapulmonary and recurrent Ewing sarcoma, remains poor [48, 49] .
What is the optimal first-line therapy in Ewing sarcoma?
The standard of care for patients with newly diagnosed Ewing sarcoma in north America is dosecompressed chemotherapy with alternating cycles of vincristine, doxorubicin and cyclophosphamide with ifosfamide and etoposide (VDC-IE) [50] . Vincristine, ifosfamide, doxorubicin and etoposide (VIDE) induction with VAI (Vincristine, actinomycin, ifosfamide) or VAC (Vincristine, actinomycin, cyclophosphamide) consolidation adopted from EURO-E.W.I.N.G 99 protocol is considered the standard of care in Europe [51] . The current EuroEwing consortium (EEC) study, EuroEwing2012, is comparing the two regimens and will help define an international standard of care. A second randomization is assessing the efficacy of zoledronic acid for localized and lung-only metastatic disease, a question also being addressed in the German collaborative, Ewing2008 study. On the basis of encouraging efficacy in recurrent disease, COG is assessing the value of addition of cyclophosphamide and topotecan to compressed VDC-IE in patients with localized disease (Table 2) .
What is the optimal local management of Ewing sarcoma?
A number of factors influence the use of surgery and/ or radiotherapy to treat the primary tumour, including primary site, size and response to treatment. Although Ewing sarcoma is known to be radiosensitive, radiotherapy as a single modality results in a high incidence of local recurrence (up to 30-35%), particularly for large tumours, and is only advised for inoperable tumours [52] . Tumour resection is recommended whenever complete or marginal resection is possible. Adjuvant radiotherapy significantly reduces local recurrence in patients with large volume tumours and those with a poor histologic response [53] . Preoperative radiation therapy is increasingly been used in patients who are expected to require radiotherapy as lower doses are required, which are likely to be associated with less long-term morbidity. PBT is increasingly being adopted for patients with inoperable tumours or those with tumours in challenging sites such as the spine with encouraging early local control rates [54] .
What is the role of high-dose chemotherapy in Ewing sarcoma?
The recent EURO-E.W.I.N.G 99 study compared the use of high-dose therapy incorporating busulfan and melphalan followed by stem cell rescue with standard consolidation chemotherapy in two cohorts of patients treated with induction chemotherapy and surgical resection. In the first R2Loc, which included patients with high-risk localized disease (large tumour volume >200 ml and/or a poor response to induction chemotherapy), the study demonstrated an improvement in 3-year event-free survival (67 vs. 53%) and 3-year OS (78 vs. 70%) and so should be considered for this group of patients [55] . No benefit was found for patients with pulmonary metastases at diagnosis (R2Pulm) and should not be recommenced in this setting [56] . There are no results of randomized studies to support the use of HDT in patients with extrapulmonary metastatic disease.
What is the optimal therapy for patients with metastatic and relapsed Ewing sarcoma?
Patients with metastases at diagnosis have a less favourable outcome, particularly those with extrapulmonary metastatic disease. Patients are treated with standard regimens; however, considerations to quality of life as well as improving outcome are required in this setting. The COG is investigating the value of addition of the IGF1R mAb, ganitumab, to interval-compressed VDC-IE in metastatic Ewing sarcoma.
In recurrent/refractory Ewing sarcoma, several combination therapies have demonstrated activity; however, evidence comes from retrospective analyses and small phase II studies and responses are generally short-lived. The rEECur study, the first EURO-Ewing Consortium (EEC) study for recurrent Ewing sarcoma, is comparing those most commonly used to identify the optimum therapy based on the efficacy and toxicity ( Table 2) . The study has a flexible, multiarm multistage phase II/III trial design that allows further arms to be added to the protocol to allow randomized investigation of promising novel therapies.
What are the emerging targets and therapies in Ewing sarcoma?
Studies describing the genomic landscape of Ewing sarcoma have demonstrated that Ewing sarcoma has a low mutational rate. The most common recurrent mutation is found in STAG2, which is found in 15% of patients. Other commonly reported genetic alterations include deletion of CDKN2A and mutations in TP53; however, to date, these findings have not led to changes in therapy [57] . On the basis of preclinical studies demonstrating sensitivity of Ewing sarcoma cell lines to PARP inhibition, and potent synergy of PARP inhibitors with temozolomide and irinotecan in Ewing sarcoma preclinical models, several international studies are investigating safety and efficacy of these combinations [58] [59] [60] ( Table 3) . Tyrosine kinase inhibitors also undergo evaluation in Ewing sarcoma with a recent study of regorafinib meeting its primary end point, with 60% patients achieving stable disease at 8 weeks [61] .
Other novel agents such as TK216, which directly targets the EWS-FLI1 interaction with a partner protein RNA helicase A, have recently entered a phase I clinical trial [62] . Inhibition of the transrepressive functions of EWSR1-FLI1 through the use of lysinespecific histone demethylase inhibitors also appears promising [63] . Response to single-agent checkpoint inhibition, however, has been disappointing and further work is required to determine the place of immunotherapy in Ewing sarcoma [41 && ].
CHONDROSARCOMA
Surgical resection of disease is the mainstay of therapy for patients with the most common subtype, conventional chondrosarcoma (Table 4) . Cure rates are high if disease is low grade, wherein extensive intralesional curettage may be considered to reduce morbidity. Intermediate and high-grade tumours, however, require wide, en-bloc resection. Dedifferentiated chondrosarcoma, which accounts for approximately 10% of chondrosarcoma, is commonly associated with development of bone and lung metastases and very poor survival. Adjuvant chemotherapy as given for osteosarcoma may be considered in younger patients with localized dedifferentiated chondrosarcoma. Patients with advanced disease and good performance may benefit from the palliative use of cisplatin and doxorubicin. In mesenchymal chondrosarcoma, adjuvant chemotherapy is associated with reduced risk of recurrence and death [64] .
What is the role of radiotherapy in chondrosarcoma?
Chondrosarcomas are considered radioresistant tumours; thus, high doses are required to be effective. PBT and CIRT, which are able to deliver doses over 70 Gy, are beginning to demonstrate benefit in chondrosarcoma with high local control rates for skull base and spinal chondrosarcomas up to 7 years after therapy with acceptable late toxicity [65, 66] .
What are the emerging targets and therapies in chondrosarcomas?
Chondrosarcomas are resistant to chemotherapy; thus, new therapeutic approaches are needed for unresectable or metastatic disease. isocitrate dehydrogenase (IDH1) and IDH2 mutations have been identified in more than 50% of patients with conventional chondrosarcoma and offers a promising new target with several clinical trials evaluating the clinical activity of novel IDH inhibitors [67] . A phase II study, investigating the efficacy and safety of pazopanib, a potent multitargeted RTK inhibitor in patients with unresectable or metastatic chondrosarcoma, has recently completed accrual (NCT01330966).
CONCLUSION
Although significant advances have been made in management of bone tumours, therapy is complex and patients require management at specialist centres. Continued collaboration is essential to answer current questions and investigate novel therapies in these malignancies to improve outcome and quality of life for patients. Ideally, studies should be conducted with standardized endpoints and biomarkers that better predict response and outcome are of paramount importance. Questions also remain how best to incorporating new agents into front-line therapy. For novel radiotherapy techniques, further follow is required to determine impact on long-term morbidity and second malignancy. 
